|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
SI1523496T1
(sl)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Rekombinantno proizvajanje zmesi protiteles
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
KR101206206B1
(ko)
*
|
2003-07-22 |
2012-11-29 |
크루셀 홀란드 비.브이. |
사스-코로나바이러스에 대한 결합분자 및 그것의 용도
|
|
CN102139106B
(zh)
*
|
2004-05-27 |
2014-10-08 |
克鲁塞尔荷兰公司 |
能中和狂犬病病毒的结合分子及其应用
|
|
JP4852046B2
(ja)
*
|
2004-10-12 |
2012-01-11 |
クルセル ホランド ベー ヴェー |
癌の治療及び検出に用いる結合分子
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
WO2006120230A2
(en)
|
2005-05-12 |
2006-11-16 |
Crucell Holland B.V. |
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
|
|
US8148085B2
(en)
|
2006-05-15 |
2012-04-03 |
Sea Lane Biotechnologies, Llc |
Donor specific antibody libraries
|
|
EP3018142A1
(en)
|
2006-06-06 |
2016-05-11 |
Crucell Holland B.V. |
Human binding molecules having killing activity against staphylococci and uses thereof
|
|
MY170607A
(en)
|
2006-09-07 |
2019-08-20 |
Crucell Holland Bv |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
|
|
EP2125886A2
(en)
|
2007-03-13 |
2009-12-02 |
Humabs LLC |
Antibodies against h5n1 strains of influenza a virus
|
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
EP2036045A1
(en)
*
|
2007-07-11 |
2009-03-18 |
Cairos technologies AG |
Video tracking method and appartus arrangement for performing the method
|
|
US8444986B2
(en)
|
2007-09-13 |
2013-05-21 |
Temasek Life Sciences Laboratory Limited |
Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof
|
|
EP2947094B1
(en)
|
2007-09-13 |
2018-11-14 |
Temasek Life Sciences Laboratory Limited |
Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
|
|
WO2009079259A2
(en)
*
|
2007-12-06 |
2009-06-25 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
|
ITTO20080204A1
(it)
|
2008-03-17 |
2009-09-18 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
|
|
AU2009228058A1
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to viral antigens
|
|
ITTO20080398A1
(it)
|
2008-05-27 |
2009-11-28 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
|
|
US8871207B2
(en)
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
|
KR20110049802A
(ko)
|
2008-07-25 |
2011-05-12 |
인스티튜트 포 리서치 인 바이오메드슨 |
중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
|
|
GB0818356D0
(en)
*
|
2008-10-07 |
2008-11-12 |
Istituto Superiore Di Sanito |
Antibodies
|
|
AR073770A1
(es)
*
|
2008-10-20 |
2010-12-01 |
Imclone Llc |
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
|
|
US9347043B2
(en)
|
2008-10-22 |
2016-05-24 |
Institute For Research In Biomedicine |
Methods for producing antibodies from plasma cells
|
|
CN102438652B
(zh)
*
|
2008-11-12 |
2014-08-13 |
米迪缪尼有限公司 |
抗体制剂
|
|
SG172333A1
(en)
|
2008-12-24 |
2011-07-28 |
Temasek Life Sciences Lab Ltd |
Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
|
|
EP3009145A1
(en)
|
2009-03-30 |
2016-04-20 |
Mount Sinai School of Medicine of New York University |
Influenza virus vaccines and uses thereof
|
|
US8894997B2
(en)
|
2009-04-30 |
2014-11-25 |
Vanderbilt University |
Monoclonal antibodies to influenza H1N1 virus uses thereof
|
|
US8470327B2
(en)
*
|
2009-05-11 |
2013-06-25 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
|
|
WO2010132604A2
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
AU2010254136B2
(en)
|
2009-05-26 |
2016-09-29 |
Mount Sinai School Of Medicine |
Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
|
|
EP2464383A4
(en)
*
|
2009-08-14 |
2013-02-13 |
Theraclone Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF FLU
|
|
US9458226B2
(en)
|
2009-10-09 |
2016-10-04 |
Emory University |
Recombinant antibodies against H1N1 influenza
|
|
AU2011210840B2
(en)
*
|
2010-01-27 |
2014-12-11 |
Massachusetts Institute Of Technology |
Engineered polypeptide agents for targeted broad spectrum influenza neutralization
|
|
BR112012020839A2
(pt)
|
2010-02-18 |
2017-11-21 |
Sinai School Medicine |
vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
|
|
JP5795340B2
(ja)
*
|
2010-03-08 |
2015-10-14 |
セルトリオン インクＣｅｌｌｔｒｉｏｎ，Ｉｎｃ． |
インフルエンザａ型ウイルスに対して中和活性を有するヒトｂ細胞由来のヒトモノクローナル抗体
|
|
JP2013526849A
(ja)
|
2010-03-30 |
2013-06-27 |
モウント シナイ スクール オフ メディシネ |
インフルエンザウイルスワクチン及びその使用
|
|
CN102241768B
(zh)
*
|
2010-05-14 |
2013-12-25 |
中国科学院上海生命科学研究院 |
一种抗甲型h1n1流感病毒血凝素蛋白的抗体
|
|
JP6050747B2
(ja)
*
|
2010-06-17 |
2016-12-21 |
トレリス バイオサイエンス リミテッド ライアビリティー カンパニー |
インフルエンザ受動免疫化に有用な抗体
|
|
CA2806250C
(en)
|
2010-07-22 |
2020-09-22 |
John W. Schrader |
Cross-protective pathogen protection, methods and compositions thereof
|
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
JP2013540701A
(ja)
*
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ， インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
|
US9534042B2
(en)
|
2010-09-03 |
2017-01-03 |
Fujita Health University |
Influenza virus-neutralizing antibody and screening method therefor
|
|
WO2012036993A1
(en)
|
2010-09-14 |
2012-03-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
|
CN103429606A
(zh)
|
2010-10-01 |
2013-12-04 |
现代治疗公司 |
设计核酸及其使用方法
|
|
EP2663334A4
(en)
*
|
2011-01-10 |
2016-01-13 |
Univ Emory |
ANTIBODIES AGAINST INFLUENZA
|
|
JP2014506580A
(ja)
*
|
2011-02-14 |
2014-03-17 |
セラクローン サイエンシーズ， インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
|
CN103649118A
(zh)
*
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012151199A1
(en)
*
|
2011-05-02 |
2012-11-08 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
RU2612900C2
(ru)
|
2011-06-20 |
2017-03-13 |
Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн |
Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
|
|
US8961978B2
(en)
*
|
2011-07-14 |
2015-02-24 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
|
|
LT2734545T
(lt)
|
2011-07-18 |
2019-05-10 |
Institute For Research In Biomedicine |
Antikūnai, neutralizuojantys influenza a virusą, ir jų panaudojimo būdai
|
|
US10300140B2
(en)
|
2011-07-28 |
2019-05-28 |
I2 Pharmaceuticals, Inc. |
Sur-binding proteins against ERBB3
|
|
WO2013033319A2
(en)
*
|
2011-08-30 |
2013-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
A cluster of neutralizing antibodies to hepatitis c virus
|
|
GB201115214D0
(en)
|
2011-09-02 |
2011-10-19 |
Health Prot Agency |
Influenza virus antibody compositions
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
BR112014006694A2
(pt)
|
2011-09-20 |
2020-11-17 |
Mount Sinai School Of Medicine |
vacinas contra o vírus influenza e usos dessas
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
KR20190099538A
(ko)
|
2011-10-03 |
2019-08-27 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
|
|
CA2852474A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Emory University |
Antibodies directed against influenza
|
|
WO2013079473A1
(en)
|
2011-11-28 |
2013-06-06 |
Crucell Holland B.V. |
Influenza virus vaccines and uses thereof
|
|
SG11201402780UA
(en)
*
|
2011-12-02 |
2014-10-30 |
Aimm Therapeutics Bv |
Influenza a virus specific antibodies
|
|
CN104302321A
(zh)
|
2011-12-05 |
2015-01-21 |
特瑞利斯生物科学有限责任公司 |
可用于被动流感免疫的抗体
|
|
KR101749316B1
(ko)
|
2011-12-15 |
2017-06-21 |
(주) 에이프로젠 |
Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
|
|
EP4144378A1
(en)
|
2011-12-16 |
2023-03-08 |
ModernaTX, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
CA2859744A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
|
RU2653756C2
(ru)
|
2012-02-07 |
2018-05-14 |
Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн |
Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
|
|
EP3305806B1
(en)
|
2012-02-13 |
2020-08-26 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
|
|
ES2664625T3
(es)
|
2012-03-08 |
2018-04-20 |
Janssen Vaccines & Prevention B.V. |
Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos
|
|
JP2015513902A
(ja)
|
2012-03-30 |
2015-05-18 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
計算で最適化した広い反応性を示す、ｈ５ｎ１およびｈ１ｎ１インフルエンザウイルスの抗原
|
|
AU2013243954A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
CA2870821C
(en)
|
2012-04-20 |
2022-06-14 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
US9969794B2
(en)
|
2012-05-10 |
2018-05-15 |
Visterra, Inc. |
HA binding agents
|
|
EP2712626A1
(en)
*
|
2012-09-28 |
2014-04-02 |
Fabentech |
Passive immunisation against influenza, in particular H5N1
|
|
PH12019501031A1
(en)
|
2012-11-13 |
2022-11-14 |
Genentech Inc |
Anti-hemagglutinin antibodies and methods of use
|
|
DK2922554T3
(en)
|
2012-11-26 |
2022-05-23 |
Modernatx Inc |
Terminalt modificeret rna
|
|
KR20150089005A
(ko)
|
2012-11-27 |
2015-08-04 |
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
H1n1에 대한 계산적으로 최적화되고 넓은 반응성의 항원
|
|
JP2016508133A
(ja)
|
2012-12-18 |
2016-03-17 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルスワクチン及びその使用
|
|
WO2014159960A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
|
EP2970397A2
(en)
|
2013-03-14 |
2016-01-20 |
University Of Washington Through Its Center For Commercialization |
Polypeptides for treating and/or limiting influenza infection
|
|
CA2906676A1
(en)
|
2013-03-14 |
2014-09-25 |
Contrafect Corporation |
Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP2982691B1
(en)
|
2013-04-02 |
2020-05-06 |
Xiamen University |
Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins
|
|
BR112015029635B1
(pt)
|
2013-05-30 |
2023-05-02 |
Janssen Vaccines & Prevention B.V |
Polipeptídeo do domínio de haste da hemaglutinina da gripe e composição
|
|
EP3037819A4
(en)
*
|
2013-08-23 |
2017-03-29 |
Fujita Health University |
Method of determining resistance to influenza virus
|
|
US20160200799A1
(en)
|
2013-08-23 |
2016-07-14 |
Fujita Health University |
Anti-influenza virus neutralizing antibody
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
LT3052192T
(lt)
|
2013-10-02 |
2020-12-10 |
Medimmune, Llc |
Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
|
|
BR112016007255A2
(pt)
|
2013-10-03 |
2017-09-12 |
Moderna Therapeutics Inc |
polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
|
|
WO2015068781A1
(ja)
*
|
2013-11-06 |
2015-05-14 |
国立大学法人大阪大学 |
インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
|
|
JP6712428B2
(ja)
|
2014-02-04 |
2020-06-24 |
コントラフェクト コーポレイション |
インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
|
|
US10639370B2
(en)
|
2014-02-04 |
2020-05-05 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
BR112016018313A8
(pt)
|
2014-02-10 |
2018-06-12 |
Igm Biosciences Inc |
Moléculas de ligação multiespecíficas iga
|
|
CA2940196C
(en)
|
2014-03-19 |
2023-03-07 |
Wayne Marasco |
Immunogenetic restriction on elicitation of antibodies
|
|
PT3981437T
(pt)
|
2014-04-23 |
2025-01-15 |
Modernatx Inc |
Vacinas de ácidos nucleicos
|
|
JP7094103B2
(ja)
*
|
2014-07-10 |
2022-07-01 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
インフルエンザウイルスワクチンおよびその使用
|
|
EP3166962B1
(en)
|
2014-07-10 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
|
AU2015289805B2
(en)
|
2014-07-15 |
2020-06-25 |
Humabs Biomed Sa |
Neutralizing anti-influenza B antibodies and uses thereof
|
|
TWI702229B
(zh)
|
2014-12-19 |
2020-08-21 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
US10736956B2
(en)
|
2015-01-23 |
2020-08-11 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
|
CA2975655C
(en)
|
2015-02-05 |
2023-09-19 |
Janssen Vaccines & Prevention B.V. |
Binding molecules directed against influenza hemagglutinin and uses thereof
|
|
WO2016124682A1
(en)
|
2015-02-05 |
2016-08-11 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza neuraminidase
|
|
CA2985402A1
(en)
|
2015-05-11 |
2016-11-17 |
Janssen Vaccines & Prevention B.V. |
Influenza virus neutralizing peptidomimetic compounds
|
|
PL3303384T3
(pl)
|
2015-06-01 |
2022-01-03 |
Medimmune, Llc |
Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania
|
|
EP3374390A1
(en)
|
2015-11-13 |
2018-09-19 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
CA3010313A1
(en)
|
2016-01-13 |
2017-07-20 |
Medimmune, Llc |
Method of treating influenza a
|
|
CA3015347A1
(en)
|
2016-02-24 |
2017-08-31 |
Visterra, Inc. |
Formulations of antibody molecules to influenza virus
|
|
WO2017148889A1
(en)
|
2016-03-01 |
2017-09-08 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza b neuraminidase
|
|
JP7237344B2
(ja)
|
2016-06-15 |
2023-03-13 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルス血球凝集素タンパク質及びその使用
|
|
KR101835009B1
(ko)
|
2016-08-19 |
2018-03-07 |
주식회사 하이딥 |
터치 입력 장치
|
|
EP3529272A2
(en)
|
2016-10-21 |
2019-08-28 |
Adimab, LLC |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
EP3974447A3
(en)
*
|
2016-10-21 |
2022-09-07 |
Adimab, LLC |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
JP2020503844A
(ja)
|
2016-10-21 |
2020-02-06 |
アディマブ， エルエルシー |
抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
|
|
AU2017350304B2
(en)
|
2016-10-27 |
2022-03-03 |
Janssen Vaccines & Prevention B.V. |
Influenza virus neutralizing compounds
|
|
EP3574008B1
(en)
|
2017-01-27 |
2023-11-08 |
National Research Council of Canada |
Hemagglutinin-specific antibodies and uses thereof
|
|
WO2018141854A1
(en)
|
2017-02-02 |
2018-08-09 |
Janssen Vaccines & Prevention B.V. |
Piperazine derivatives for influenza virus inhibition
|
|
US11040963B2
(en)
|
2017-02-02 |
2021-06-22 |
Janssen Vaccines & Prevention B.V. |
Piperazine derivatives for influenza virus inhibitions
|
|
JP2020506971A
(ja)
|
2017-02-08 |
2020-03-05 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
|
|
SG11201907646YA
(en)
|
2017-02-20 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Proteins binding her2, nkg2d and cd16
|
|
EP3606964A4
(en)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
|
|
EP3606555A4
(en)
|
2017-04-07 |
2021-08-04 |
Icahn School of Medicine at Mount Sinai |
INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
|
|
WO2019035630A2
(ko)
*
|
2017-08-14 |
2019-02-21 |
사회복지법인 삼성생명공익재단 |
인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편
|
|
EP3681903B1
(en)
*
|
2017-09-15 |
2023-07-19 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19 immunotherapy
|
|
SMT202200354T1
(it)
|
2018-01-23 |
2022-09-14 |
Janssen Vaccines & Prevention Bv |
Vaccino per virus dell'influenza e suoi usi
|
|
JP7372925B2
(ja)
|
2018-01-26 |
2023-11-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
インフルエンザヘマグルチニンに対するヒト抗体
|
|
PE20210375A1
(es)
|
2018-02-08 |
2021-03-02 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
|
|
FI3749346T3
(fi)
|
2018-02-08 |
2024-09-04 |
Dragonfly Therapeutics Inc |
Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
|
|
MX2020008684A
(es)
|
2018-02-20 |
2020-12-07 |
Dragonfly Therapeutics Inc |
Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
|
|
WO2019246363A1
(en)
|
2018-06-21 |
2019-12-26 |
Icahn School Of Medicine At Mount Sinai |
Mosaic influenza virus hemagglutinin polypeptides and uses thereof
|
|
US12384851B2
(en)
|
2018-08-08 |
2025-08-12 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
JP7482363B2
(ja)
|
2018-08-08 |
2024-05-14 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
|
|
CN111057718A
(zh)
*
|
2018-10-17 |
2020-04-24 |
南京大学 |
一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法
|
|
KR102113302B1
(ko)
*
|
2018-12-24 |
2020-05-20 |
원광대학교산학협력단 |
상보성결정부 기반 조류 인플루엔자 바이러스의 h5 아형에 특이적으로 결합하는 펩티드 및 이의 용도
|
|
EP3946613A1
(en)
|
2019-03-25 |
2022-02-09 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
CA3152957A1
(en)
|
2019-09-05 |
2021-03-11 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
|
CN111440228B
(zh)
*
|
2020-03-09 |
2021-08-24 |
扬州大学 |
多种亚型流感病毒ha2蛋白共同抗原表位、抗体、鉴定方法和应用
|
|
WO2021201677A1
(en)
|
2020-04-01 |
2021-10-07 |
Kiadis Pharma Intellectual Property B.V. |
Compositions and methods targeting influenza
|
|
US20210325367A1
(en)
*
|
2020-04-20 |
2021-10-21 |
Satish Mahna |
Controlled Exposure to Pathogens for Generating Immunity
|
|
TW202208428A
(zh)
|
2020-05-06 |
2022-03-01 |
美商蜻蜓醫療公司 |
結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
|
|
CN116761605A
(zh)
*
|
2021-02-04 |
2023-09-15 |
四川海思科制药有限公司 |
Ha抑制剂化合物的盐及晶型
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
TW202309075A
(zh)
*
|
2021-04-30 |
2023-03-01 |
美商亞得捷歐治療公司 |
對冠狀病毒s蛋白質具特異性之化合物及其用途
|
|
WO2024104947A2
(en)
|
2022-11-14 |
2024-05-23 |
Janssen Vaccines & Prevention B.V. |
Influenza b virus vaccines and uses thereof
|
|
WO2025019631A1
(en)
|
2023-07-19 |
2025-01-23 |
Icahn School Of Medicine At Mount Sinai |
Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
|
|
US20250090650A1
(en)
|
2023-09-06 |
2025-03-20 |
Sanofi |
Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2025090499A1
(en)
*
|
2023-10-24 |
2025-05-01 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Monoclonal antibodies that bind an antigen of epithelial ovarian cancer and their use
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|